Larotrectinib
See how this compound is being investigated across Bayer’s oncology pipeline
Explore the tumor types, areas of research, and clinical trials associated with this investigational compound.
Compound Overview
Larotrectinib is a tropomyosin receptor kinase (TRK) inhibitor that results in ligand-independent, constitutive activation of TRK receptor signaling. Larotrectinib exhibits anti-tumor activity through blockade of constitutive TRK signaling and the resulting overstimulation of downstream pathways involved in cell growth and survival.1,2
Larotrectinib is being investigated in adults and children for the treatment of patients with cancers that harbor an NTRK gene fusion.3
Please note: there will be no new interventional studies with larotrectinib.
Clinical Trials
Tumor Type(s) | Phase | Status | Description | NCT Number |
|---|---|---|---|---|
Solid Tumors | I, II | Active, Not Enrolling | A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors | |
Solid Tumors | Non-interventional Study | Now Enrolling | Prospective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib | |
Solid Tumors | Non-interventional Study | Now Enrolling | Special Drug Use Investigation for Larotrectinib |
Bayer’s Oncology Pipeline Brochure
Explore a comprehensive overview of Bayer's oncology pipeline, including investigational compounds, clinical trials, and areas of research.
The ongoing clinical trials listed on this website represent a comprehensive overview of Bayer's clinical pipeline in Oncology, including Bayer-sponsored research and collaborative research with academic centers, cooperative groups, and other global institutions.